Phase Ib multicenter study of trastuzumab deruxtecan (T-DXd) and immunotherapy with or without chemotherapy in first-line treatment of patients (pts) with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (OE): DESTINY-Lung03

被引：4

作者：

Planchard, D. ^{[1
]}

Brahmer, J. R. ^{[2
]}

Yang, J. C-H. ^{[3
]}

Kim, H. R. ^{[4
]}

Li, R. K. ^{[5
]}

Han, J-Y. ^{[6
]}

Cortinovis, D. L. ^{[7
]}

Runglodvatana, Y. ^{[8
]}

Nakajima, E. ^{[9
]}

Ragone, A. ^{[10
]}

Winter, M. ^{[11
]}

Gustavson, M. ^{[12
]}

机构：

[1] Inst Gustave Roussy, Dept Med Oncol, Villejuif, France

[2] Johns Hopkins Kimmel Canc Ctr, Thorac Oncol Program, Baltimore, MD USA

[3] Natl Taiwan Univ Hosp, Dept Med Oncol, Taipei, Taiwan

[4] Yonsei Canc Ctr, Div Med Oncol, Dept Internal Med, Seoul, South Korea

[5] St Lukes Med Ctr Quezon City, Dept Med Oncol, Quezon City, Philippines

[6] Natl Canc Ctr, Ctr Lung Canc, Grad Sch Canc Sci & Policy, Goyang, South Korea

[7] Fondazione IRCCS San Gerardo dei Tintori, SC Oncol Med, Monza, Italy

[8] Navamindradhiraj Univ, Div Med Oncol, Vajira Hosp, Fac Med, Bangkok, Thailand

[9] AstraZeneca, Late Dev Oncol, R&D, Gaithersburg, MD USA

[10] AstraZe neca, Late Dev Oncol, R&D, Mississauga, ON, Canada

[11] AstraZeneca, Data Sci & Quantitat Biol, Cambridge, England

[12] AstraZeneca, Translat Med, Oncol R&D, Gaithersburg, MD USA

来源：

ANNALS OF ONCOLOGY | 2023年 / 34卷

关键词：

D O I：

10.1016/j.annonc.2023.09.2538

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

1507TiP

引用

页数：2

共 50 条

[1] A phase Ib dose-escalation study evaluating trastuzumab deruxtecan (T-DXd) and durvalumab in combination with chemotherapy as first-line treatment in patients with advanced or metastatic nonsquamous non-small cell lung cancer (NSCLC) and HER2 overexpression (DESTINY-Lung03)
Planchard, D.
Yang, J. C-H.
Brahmer, J. R.
Ragone, A.
Chen, J.
Liu, F.
Saggese, M.
JOURNAL OF THORACIC ONCOLOGY, 2021, 16 (04) : S798 - S798
[2] Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): A phase (ph) II study (DESTINY-Lung02)
Smit, E. F. F.
Li, B. T.
Mazieres, J.
Planchard, D.
Nakagawa, K.
Goto, K.
Paz-Ares, L.
Novello, S.
Yang, J. C-H.
Ahn, M-J.
Liu, G.
O'Byrne, K.
Aregay, M.
Shiga, R.
Saxena, K.
Meinhardt, G.
Janne, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1032 - S1033
[3] Trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutant metastatic non-small cell lung cancer (NSCLC): Interim results from the phase 2 DESTINY-Lung02 trial
Goto, K.
Sang-We, K.
Kubo, T.
Goto, Y.
Ahn, M-J.
Planchard, D.
Kim, D-W.
Yang, J. C-H.
Yang, T-Y.
Pereira, K. M. C.
Saxena, K.
Shiga, R.
Cheng, Y.
Aregay, M.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1422 - S1422
[4] Trastuzumab deruxtecan (T-DXd; DS-8201) in combination with pembrolizumab in patients with advanced/metastatic breast or non-small cell lung cancer (NSCLC): A phase Ib, multicenter, study.
Borghaei, Hossein
Besse, Benjamin
Bardia, Aditya
Mazieres, Julien
Popat, Sanjay
Augustine, Bincy
D'amelio, Anthony Michael
Barrios, Daniel
Rugo, Hope S.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[5] Trastuzumab Deruxtecan Monotherapy in Pretreated HER2-overexpressing Nonsquamous Non-Small Cell Lung Cancer: DESTINY-Lung03 Part 1
Planchard, D.
Kim, H. R.
Suksombooncharoen, T.
Li, R.
Samol, J.
Runglodvatana, Y.
Lee, K. -Y.
Chang, G. -C.
Kowalski, D.
Han, J. -Y.
Saw, S.
Huang, Y.
Sookprasert, A.
Nakajima, E.
Alfon, J.
Chang, Y. -T.
Yang, J. C. -H.
JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (10) : S46 - S47
[6] Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non-small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04).
Li, Bob T.
Ahn, Myung-Ju
Goto, Koichi
Mazieres, Julien
Padda, Sukhmani Kaur
William, Nassib William
Wu, Yi-Long
Dearden, Simon
Ragone, Alejandra
Viglianti, Natasha
Gasco, Amaya
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
[7] Phase 1b dose-escalation and dose-expansion study evaluating trastuzumab deruxtecan (T-DXd) in combination with durvalumab and cisplatin, carboplatin, or pemetrexed in advanced or metastatic, HER2-overexpressing, nonsquamous non-small cell lung cancer (NSCLC): DESTINY-Lung03
Planchard, David
Brahmer, Julie R.
Yang, James C.
Chen, Yuh-Min
Lee, Kang-Yun
Suksombooncharoen, Thatthan
Viglianti, Natasha
Gustavson, Mark
Ragone, Alejandra
Hernandez, Amaya Gasco
CANCER RESEARCH, 2022, 82 (12)
[8] Primary data from DESTINY-Lung01: A phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC)
Li, B. T.
Smit, E. F. F.
Goto, Y.
Nakagawa, K.
Udagawa, H.
Mazieres, J.
Nagasaka, M.
Bazhenova, L.
Saltos, A. N.
Felip, E.
Pacheco, J. M.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Acharyya, S.
Shahidi, J.
Planchard, D.
Janne, P. A.
ANNALS OF ONCOLOGY, 2021, 32 : S1323 - S1324
[9] Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01
Li, B. T.
Smit, E. F.
Goto, Y.
Nakagawa, K.
Goto, K.
Mazieres, J.
Uprety, D.
Bazhenova, L.
Saltos, A.
Felip, E.
Pacheco, J.
Perol, M.
Paz-Ares, L.
Saxena, K.
Shiga, R.
Cheng, Y.
Yan, Q.
Planchard, D.
Janne, P. A.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S995 - S996
[10] Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-mutated metastatic non-small cell lung cancer (NSCLC): Interim results of DESTINY-Lung01.
Smit, Egbert F.
Nakagawa, Kazuhiko
Nagasaka, Misako
Felip, Enriqueta
Goto, Yasushi
Li, Bob T.
Pacheco, Jose Maria
Murakami, Haruyasu
Barlesi, Fabrice
Saltos, Andreas Nicholas
Perol, Maurice
Udagawa, Hibiki
Saxena, Kapil
Shiga, Ryota
Guevara, Ferdinand M.
Acharyya, Suddhasatta
Shahidi, Javad
Planchard, David
Janne, Pasi A.
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)

← 1 2 3 4 5 →